Price T Rowe Associates Inc Novo Cure LTD Transaction History

Price T Rowe Associates Inc

$883 Billion
Q2 2025

A detailed history of Price T Rowe Associates Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Price T Rowe Associates Inc holds 105,751 shares of NVCR stock, worth $1.35 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

105,751

Previous 482,034 78.06%

Holding current value

$1.35 Million

Previous $8.59 Million 78.08%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 14, 2025	SELL	$15.37 - $19.4 $5.78 Million - $7.3 Million	-376,283 Reduced 78.06%	105,751 $1.88 Million
Q1 2025 May 14, 2025	SELL	$17.82 - $30.19 $21.4 Million - $36.3 Million	-1,201,784 Reduced 71.37%	482,034 $8.59 Million
Q4 2024 Feb 14, 2025	SELL	$14.54 - $33.41 $9.28 Million - $21.3 Million	-638,378 Reduced 27.49%	1,683,818 $50.2 Million
Q3 2024 Nov 14, 2024	BUY	$15.61 - $23.34 $2.59 Million - $3.88 Million	166,175 Added 7.71%	2,322,196 $36.3 Million
Q2 2024 Aug 14, 2024	SELL	$11.83 - $24.05 $2.64 Million - $5.36 Million	-222,919 Reduced 9.37%	2,156,021 $36.9 Million
Q1 2024 May 15, 2024	BUY	$12.42 - $17.29 $1.56 Million - $2.17 Million	125,715 Added 5.58%	2,378,940 $37.2 Million
Q4 2023 Feb 14, 2024	SELL	$11.13 - $15.78 $1.24 Million - $1.76 Million	-111,234 Reduced 4.7%	2,253,225 $33.6 Million
Q3 2023 Nov 14, 2023	SELL	$16.15 - $42.35 $2.92 Million - $7.67 Million	-181,006 Reduced 7.11%	2,364,459 $38.2 Million
Q2 2023 Aug 14, 2023	SELL	$40.29 - $82.51 $4.44 Million - $9.09 Million	-110,221 Reduced 4.15%	2,545,465 $106 Million
Q1 2023 May 15, 2023	BUY	$56.44 - $118.81 $27.5 Million - $57.9 Million	487,255 Added 22.47%	2,655,686 $160 Million
Q4 2022 Feb 14, 2023	SELL	$63.98 - $85.37 $13 Million - $17.4 Million	-203,555 Reduced 8.58%	2,168,431 $159 Million
Q3 2022 Nov 14, 2022	BUY	$67.99 - $89.57 $2.76 Million - $3.64 Million	40,619 Added 1.74%	2,371,986 $180 Million
Q2 2022 Aug 15, 2022	BUY	$56.6 - $89.9 $12.4 Million - $19.6 Million	218,216 Added 10.33%	2,331,367 $162 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $37.7 Million - $53 Million	626,983 Added 42.19%	2,113,151 $175 Million
Q4 2021 Feb 14, 2022	BUY	$75.08 - $121.99 $4.03 Million - $6.55 Million	53,701 Added 3.75%	1,486,168 $112 Million
Q3 2021 Nov 15, 2021	SELL	$116.17 - $194.55 $15.9 Million - $26.7 Million	-137,018 Reduced 8.73%	1,432,467 $166 Million
Q2 2021 Aug 16, 2021	BUY	$130.4 - $225.58 $44.6 Million - $77.1 Million	341,783 Added 27.84%	1,569,485 $348 Million
Q1 2021 May 17, 2021	SELL	$124.11 - $190.17 $1.3 Million - $2 Million	-10,502 Reduced 0.85%	1,227,702 $162 Million
Q4 2020 Feb 16, 2021	BUY	$112.16 - $174.14 $139 Million - $216 Million	1,238,204 New	1,238,204 $214 Million

Others Institutions Holding NVCR

# of Institutions

284

Shares Held

77.5M

Call Options Held

943K

Put Options Held

155K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.33B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Price T Rowe Associates Inc , based on Form 13F filings with the SEC.

News

Stay updated on Price T Rowe Associates Inc with notifications on news.

Account

Price T Rowe Associates Inc Novo Cure LTD Transaction History